Molecular Partners' 'Smart Bomb' Shows Precision in First Human Data

ZURICH, Switzerland – February 02, 2026 – In the relentless search for more effective cancer treatments, precision is the holy grail. Biotech firm Molecular Partners today unveiled early but compelling human data that suggests its novel drug candidate, MP0712, may be a significant step forward in achieving that precision, particularly for some of the most aggressive and difficult-to-treat cancers.

Presenting at the 8th Theranostics World Congress in Cape Town, the clinical-stage company announced that its DLL3-targeting Radio-DARPin, MP0712, demonstrated highly specific tumor accumulation while largely sparing healthy tissue in the first-ever patient evaluations. The data, derived from five patients with small cell lung cancer (SCLC) and other neuroendocrine cancers, provides a crucial initial validation for the company's innovative Radio-DARPin platform and its potential to deliver potent, targeted radiation therapy.

A New Precision Weapon Takes Aim

The data presented came from a compassionate use program in South Africa, a crucial first look at how MP0712 behaves in the human body. Using a diagnostic version of the drug labeled with the isotope lead-203 (203Pb), researchers were able to visualize exactly where the drug traveled. The results were highly encouraging.

Images showed that MP0712 successfully sought out and accumulated in tumor lesions known to express the target protein, DLL3. Just as importantly, the drug showed limited uptake in healthy organs, a critical factor for minimizing the debilitating side effects often associated with systemic cancer therapies, especially radiotherapy.

“I am highly encouraged by the data generated in my group suggesting a favorable distribution profile of MP0712,” said Dr. Mike Sathekge, Professor and Head of Nuclear Medicine at the University of Pretoria, who led the study. “During the imaging step with 203Pb, we observed in our patients a promising tumor uptake, paired with a clean profile in healthy organs indicating a therapeutic potential for MP0712.”

This “theranostic” approach is a cornerstone of modern nuclear medicine. By using a diagnostic isotope (203Pb) that is chemically identical to the therapeutic isotope (in this case, the potent alpha-emitter lead-212, or 212Pb), doctors can first visualize the target and confirm the drug will reach the cancer before administering the therapeutic dose. The positive imaging and dosimetry data from this initial study provide strong support for the design of the ongoing U.S. Phase 1/2a clinical trial, which will use the therapeutic 212Pb version of MP0712.

The Science of Radio-DARPins

At the heart of this new approach is Molecular Partners' proprietary DARPin (Designed Ankyrin Repeat Protein) technology. DARPins are a novel class of small, engineered proteins designed to bind to specific targets with high affinity and specificity, much like antibodies, but with several key structural advantages for radiotherapy.

Their small size allows them to penetrate dense tumors more effectively than larger antibodies and, crucially, enables them to be cleared rapidly from the bloodstream and healthy tissues. This rapid clearance is paramount for a radiopharmaceutical, as it drastically reduces the body's overall exposure to radiation, thereby improving the safety profile. The company has further engineered MP0712 to have a tunable half-life, allowing it to linger just long enough at the tumor site to deliver its deadly payload.

That payload is lead-212, a powerful alpha-emitting isotope supplied by co-development partner Orano Med. Alpha particles are like microscopic demolition charges—they release a large amount of energy over a very short distance, typically just a few cells. This allows them to create double-strand breaks in the DNA of cancer cells, killing them effectively while sparing adjacent healthy cells from collateral damage. This high-potency, short-range attack is particularly promising for killing cancer cells that may be resistant to other forms of treatment.

Hope for Intractable Cancers

The target of MP0712, a protein called DLL3, is what makes this approach particularly relevant for patients with SCLC and other high-grade neuroendocrine tumors. DLL3 is highly expressed on the surface of these cancer cells—found in about 80-90% of SCLC tumors—but is largely absent from healthy adult tissues. This makes it an ideal “zip code” for a targeted therapy to deliver its payload exclusively to the cancer.

Small cell lung cancer remains one of the most challenging cancers to treat. It is incredibly aggressive, metastasizes early, and although it often responds to initial chemotherapy, it almost invariably returns, with subsequent treatment options offering limited benefit. The five-year survival rate is dismally low, and the need for new therapeutic modalities is urgent.

“The clinical data presented at TWC 2026 validate our assumptions and support the ongoing U.S. Phase 1/2a study, enabling us to initiate dosing of MP0712 within a potentially therapeutic range,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. “These encouraging results reinforce our ambition to become a leader in alpha‑targeted therapies for patients with small cell lung cancer and other neuroendocrine malignancies.”

The Road Ahead

While the initial data is promising, the journey for MP0712 is just beginning. The drug is now being evaluated in a formal Phase 1/2a clinical trial in the U.S. (NCT07278479), which is actively recruiting patients. This study will formally assess the safety, tolerability, and recommended dose of the therapeutic version of MP0712 carrying 212Pb.

Molecular Partners expects to report the first safety and activity data from this pivotal U.S. study in 2026. Oncologists, investors, and patients will be watching closely. For a patient population facing dire prognoses, this early glimpse of a highly precise, potent new therapy offers a tangible glimmer of hope on the horizon.